Concentrates of plasma factors such as factor VIII and factor IX for the treatment of bleeding diseases have for many years been one of Biotest’s mainstays. Constant improvement and further clinical development of our licensed products plus expansion of the range of clotting factors are a special area of interest in haematology.
A second focus is in the area of haematological oncology. Biotest is working on the development of Indatuximab Ravtansine (BT-062), an immune conjugate for the targeted therapy of multiple myeloma. Immune conjugates, also known as antibody-drug conjugates, are a new class of biological medicines. They combine the targeted action of monoclonal antibodies with the toxic properties of a chemotherapeutic drug. Only after the immune conjugate binds to the cancer cell and is absorbed into it, the toxin is released. Cancer cells are thereby combated very effectively and at the same time the effect on healthy cells is reduced compared with pure systemic chemotherapy.
In addition, studies of Indatuximab Ravtansine (BT-062) are ongoing on extending the indication to solid tumors. Its use in triple negative metastatic breast and bladder cancer is being investigated clinically.